178 related articles for article (PubMed ID: 38060692)
1. A Comprehensive Study on Nanoparticle Drug Delivery to the Brain: Application of Machine Learning Techniques.
Yousfan A; Al Rahwanji MJ; Hanano A; Al-Obaidi H
Mol Pharm; 2024 Jan; 21(1):333-345. PubMed ID: 38060692
[TBL] [Abstract][Full Text] [Related]
2. The in vivo fate of nanoparticles and nanoparticle-loaded microcapsules after oral administration in mice: Evaluation of their potential for colon-specific delivery.
Ma Y; Fuchs AV; Boase NR; Rolfe BE; Coombes AG; Thurecht KJ
Eur J Pharm Biopharm; 2015 Aug; 94():393-403. PubMed ID: 26117186
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.
Xia H; Gao X; Gu G; Liu Z; Zeng N; Hu Q; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Biomaterials; 2011 Dec; 32(36):9888-98. PubMed ID: 21937105
[TBL] [Abstract][Full Text] [Related]
4. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
[TBL] [Abstract][Full Text] [Related]
5. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
6. PTML Model for Selection of Nanoparticles, Anticancer Drugs, and Vitamins in the Design of Drug-Vitamin Nanoparticle Release Systems for Cancer Cotherapy.
Santana R; Zuluaga R; Gañán P; Arrasate S; Onieva E; Montemore MM; González-Díaz H
Mol Pharm; 2020 Jul; 17(7):2612-2627. PubMed ID: 32459098
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
[TBL] [Abstract][Full Text] [Related]
8. How Nanoparticle Physicochemical Parameters Affect Drug Delivery to Cells in the Retina via Systemic Interactions.
You Q; Sokolov M; Grigartzik L; Hintz W; van Wachem BGM; Henrich-Noack P; Sabel BA
Mol Pharm; 2019 Dec; 16(12):5068-5075. PubMed ID: 31609624
[TBL] [Abstract][Full Text] [Related]
9. Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study.
Schlachet I; Moshe Halamish H; Sosnik A
Molecules; 2020 Sep; 25(19):. PubMed ID: 33008001
[TBL] [Abstract][Full Text] [Related]
10. Intranasal administration of edaravone nanoparticles improves its stability and brain bioavailability.
Lu Y; Wang JT; Li N; Zhu X; Li Y; Bansal S; Wang Y; Al-Jamal KT
J Control Release; 2023 Jul; 359():257-267. PubMed ID: 37290723
[TBL] [Abstract][Full Text] [Related]
11. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration.
Wen Z; Yan Z; He R; Pang Z; Guo L; Qian Y; Jiang X; Fang L
Drug Deliv; 2011 Nov; 18(8):555-61. PubMed ID: 21812752
[TBL] [Abstract][Full Text] [Related]
12. Effects of cartilage-targeting moieties on nanoparticle biodistribution in healthy and osteoarthritic joints.
Brown SB; Wang L; Jungels RR; Sharma B
Acta Biomater; 2020 Jan; 101():469-483. PubMed ID: 31586725
[TBL] [Abstract][Full Text] [Related]
13. Utilizing the Lung as a Model to Study Nanoparticle-Based Drug Delivery Systems.
McDaniel DK; Ringel-Scaia VM; Coutermarsh-Ott SL; Allen IC
Methods Mol Biol; 2018; 1831():179-190. PubMed ID: 30051432
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin.
Ruan Y; Yao L; Zhang B; Zhang S; Guo J
Drug Dev Ind Pharm; 2012 Jan; 38(1):123-8. PubMed ID: 21721852
[TBL] [Abstract][Full Text] [Related]
15. Data Analytics Approach for Rational Design of Nanomedicines with Programmable Drug Release.
Mullis AS; Broderick SR; Binnebose AM; Peroutka-Bigus N; Bellaire BH; Rajan K; Narasimhan B
Mol Pharm; 2019 May; 16(5):1917-1928. PubMed ID: 30973741
[TBL] [Abstract][Full Text] [Related]
16. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
17. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.
Mittal D; Md S; Hasan Q; Fazil M; Ali A; Baboota S; Ali J
Drug Deliv; 2016; 23(1):130-9. PubMed ID: 24786489
[TBL] [Abstract][Full Text] [Related]
18. The role of nanoparticles in the improvement of systemic anticancer drug delivery.
Field LD; Nag OK; Sangtani A; Burns KE; Delehanty JB
Ther Deliv; 2018 Jul; 9(7):527-545. PubMed ID: 29943689
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
20. Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: effect of material used and surface modification.
Joseph E; Saha RN
Drug Dev Ind Pharm; 2017 Apr; 43(4):678-686. PubMed ID: 28044468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
